{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:57:36Z","timestamp":1785473856506,"version":"3.56.0"},"reference-count":25,"publisher":"The Journal of Rheumatology","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>Interleukin (IL)-17 and IL-23 inhibitors are both approved for the treatment of moderate-to-severe plaque psoriasis (PsO), as well as psoriatic arthritis (PsA). In the absence of head-to-head studies, it is not clear which agent is better suited to treat patients with moderate-to-severe PsO and mild PsA. During the 2022 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) conference, Dr. April Armstrong and Dr. Joseph Merola debated which of these 2 biologic classes should be used in this patient population. Armstrong argued in favor of IL-17 inhibition, whereas Merola presented reasons for IL-23 inhibition. An overview of their main arguments is described in this manuscript.<\/jats:p>","DOI":"10.3899\/jrheum.2023-0511","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T12:20:15Z","timestamp":1688732415000},"page":"11-13","source":"Crossref","is-referenced-by-count":7,"title":["Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics?"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5476-8494","authenticated-orcid":false,"given":"Rosario","family":"Ag\u00fcero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5057-557X","authenticated-orcid":false,"given":"Michael J.","family":"Woodbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-6036","authenticated-orcid":false,"given":"Kathryn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-6222","authenticated-orcid":false,"given":"Hanna J.","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"2023110105251428000_50.Suppl_2.11.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2023110105251428000_50.Suppl_2.11.2","unstructured":"Mease P , Landew\u00e9 R , Rahman P , Effect of SEC on radiographic progression through 2 years in patients with active psoriatic arthritis: end-of-study results from a phase III study [abstract]. Arthritis Rheumatol 2019;71 Suppl 10."},{"key":"2023110105251428000_50.Suppl_2.11.3","unstructured":"Data on file . CAIN457F2342 Clinical study report interim analysis \u2013 week 24. Novartis Pharmaceuticals Corporation; 2018."},{"key":"2023110105251428000_50.Suppl_2.11.4","unstructured":"Cosentyx . Prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2021."},{"key":"2023110105251428000_50.Suppl_2.11.5","unstructured":"Data on file . CAIN457F2342 (FUTURE 5): 2-Year Data Analysis Report. Novartis Pharmaceuticals Corp.; May 2019."},{"key":"2023110105251428000_50.Suppl_2.11.6","unstructured":"Cosentyx [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2021."},{"key":"2023110105251428000_50.Suppl_2.11.7","unstructured":"Taltz [package insert]. Indianapolis, Indiana: Eli Lilly and Company; 2020."},{"key":"2023110105251428000_50.Suppl_2.11.8","unstructured":"Skyrizi [package insert]. North Chicago, Illinois: AbbVie Inc.; 2022."},{"key":"2023110105251428000_50.Suppl_2.11.9","unstructured":"Tremfya [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2020."},{"key":"2023110105251428000_50.Suppl_2.11.10","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1957-0"},{"key":"2023110105251428000_50.Suppl_2.11.11","unstructured":"Ogdie A , Gladman D , Coates L , SEC provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of 5 phase 3 studies [abstract]. Arthritis Rheumatol 2021;73 Suppl 9."},{"key":"2023110105251428000_50.Suppl_2.11.12","unstructured":"Huscher D , Albrecht K , Bischoff S , Patients with psoriatic arthritis and oligoarthritic subtype report higher disease burden than patients with a polyarthritic pattern \u2013 data from the German Collaborative Arthritis Centres [abstract]. Arthritis Rheumatol 2015;67 Suppl 10."},{"key":"2023110105251428000_50.Suppl_2.11.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808"},{"key":"2023110105251428000_50.Suppl_2.11.14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2023110105251428000_50.Suppl_2.11.15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023110105251428000_50.Suppl_2.11.16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341"},{"key":"2023110105251428000_50.Suppl_2.11.17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023110105251428000_50.Suppl_2.11.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"2023110105251428000_50.Suppl_2.11.19","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2023110105251428000_50.Suppl_2.11.20","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1111\/jdv.18475","article-title":"The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2","volume":"36","author":"Kristensen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023110105251428000_50.Suppl_2.11.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"2023110105251428000_50.Suppl_2.11.22","doi-asserted-by":"crossref","first-page":"iv28","DOI":"10.1093\/rheumatology\/keab617","article-title":"IL-23 and axial disease: do they come together?","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"2023110105251428000_50.Suppl_2.11.23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15653"},{"key":"2023110105251428000_50.Suppl_2.11.24","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00451-w"},{"key":"2023110105251428000_50.Suppl_2.11.25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/PPA.S85773","article-title":"Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis","volume":"9","author":"Zhang","year":"2015","journal-title":"Patient Prefer Adherence"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-0511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T12:30:35Z","timestamp":1698841835000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-0511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":25,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.3899\/jrheum.2023-0511"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-0511","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}